118 related articles for article (PubMed ID: 16989600)
1. Therapeutic potential of S179D prolactin--from prostate cancer to angioproliferative disorders: the first selective prolactin receptor modulator.
Walker AM
Expert Opin Investig Drugs; 2006 Oct; 15(10):1257-67. PubMed ID: 16989600
[TBL] [Abstract][Full Text] [Related]
2. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice.
Xu X; Kreye E; Kuo CB; Walker AM
Cancer Res; 2001 Aug; 61(16):6098-104. PubMed ID: 11507059
[TBL] [Abstract][Full Text] [Related]
3. S179D prolactin increases vitamin D receptor and p21 through up-regulation of short 1b prolactin receptor in human prostate cancer cells.
Wu W; Ginsburg E; Vonderhaar BK; Walker AM
Cancer Res; 2005 Aug; 65(16):7509-15. PubMed ID: 16103106
[TBL] [Abstract][Full Text] [Related]
4. S179D prolactin sensitizes human prostate cancer cells such that physiological concentrations of 1, 25 dihydroxy vitamin D3 result in growth inhibition and cell death.
Wu W; Zanello L; Walker AM
Prostate; 2007 Oct; 67(14):1498-506. PubMed ID: 17680631
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL.
Schroeder MD; Brockman JL; Walker AM; Schuler LA
Endocrinology; 2003 Dec; 144(12):5300-7. PubMed ID: 12970160
[TBL] [Abstract][Full Text] [Related]
6. Different biological effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin involve different signaling pathways.
Wu W; Coss D; Lorenson MY; Kuo CB; Xu X; Walker AM
Biochemistry; 2003 Jun; 42(24):7561-70. PubMed ID: 12809512
[TBL] [Abstract][Full Text] [Related]
7. Prolactin increases survival and migration of ovarian cancer cells: importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists.
Tan D; Chen KE; Khoo T; Walker AM
Cancer Lett; 2011 Nov; 310(1):101-8. PubMed ID: 21775057
[TBL] [Abstract][Full Text] [Related]
8. Intracerebroventricular administration of the prolactin (PRL) receptor antagonist, S179D PRL, disrupts parturition in rats.
Nephew BC; Amico J; Cai HM; Walker AM; Bridges RS
Reproduction; 2007 Jul; 134(1):155-60. PubMed ID: 17641097
[TBL] [Abstract][Full Text] [Related]
9. Prolactin receptor antagonists.
Walker AM
Curr Opin Investig Drugs; 2005 Apr; 6(4):378-85. PubMed ID: 15898345
[TBL] [Abstract][Full Text] [Related]
10. Opposite effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin on morphology and the expression of prostate specific genes in the normal rat prostate.
Xu X; Wu W; Williams V; Khong A; Chen YH; Deng C; Walker AM
Prostate; 2003 Jan; 54(1):25-33. PubMed ID: 12481252
[TBL] [Abstract][Full Text] [Related]
11. Central infusions of the recombinant human prolactin receptor antagonist, S179D-PRL, delay the onset of maternal behavior in steroid-primed, nulliparous female rats.
Bridges R; Rigero B; Byrnes E; Yang L; Walker A
Endocrinology; 2001 Feb; 142(2):730-9. PubMed ID: 11159845
[TBL] [Abstract][Full Text] [Related]
12. Discovery of the improved antagonistic prolactin variants by library screening.
Liu Y; Gong W; Breinholt J; Nørskov-Lauritsen L; Zhang J; Ma Q; Chen J; Panina S; Guo W; Li T; Zhang J; Kong M; Liu Z; Mao J; Christensen L; Hu S; Wang L
Protein Eng Des Sel; 2011 Nov; 24(11):855-60. PubMed ID: 21954059
[TBL] [Abstract][Full Text] [Related]
13. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract][Full Text] [Related]
14. S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist.
Bernichtein S; Kinet S; Jeay S; Llovera M; Madern D; Martial JA; Kelly PA; Goffin V
Endocrinology; 2001 Sep; 142(9):3950-63. PubMed ID: 11517174
[TBL] [Abstract][Full Text] [Related]
15. Development and potential clinical uses of human prolactin receptor antagonists.
Goffin V; Bernichtein S; Touraine P; Kelly PA
Endocr Rev; 2005 May; 26(3):400-22. PubMed ID: 15814850
[TBL] [Abstract][Full Text] [Related]
16. S179D prolactin: antagonistic agony!
Walker AM
Mol Cell Endocrinol; 2007 Sep; 276(1-2):1-9. PubMed ID: 17669587
[TBL] [Abstract][Full Text] [Related]
17. Prolactin receptor antagonists.
Kuo CB; Coss D; Walker AM
Endocrine; 1998 Oct; 9(2):121-31. PubMed ID: 9867245
[TBL] [Abstract][Full Text] [Related]
18. Both prolactin (PRL) and a molecular mimic of phosphorylated PRL, S179D-PRL, protect the hippocampus of female rats against excitotoxicity.
Morales T; Lorenson M; Walker AM; Ramos E
Neuroscience; 2014 Jan; 258():211-7. PubMed ID: 24252319
[TBL] [Abstract][Full Text] [Related]
19. Long term increased expression of the short form 1b prolactin receptor in PC-3 human prostate cancer cells decreases cell growth and migration, and causes multiple changes in gene expression consistent with reduced invasive capacity.
Huang KT; Walker AM
Prostate; 2010 Jan; 70(1):37-47. PubMed ID: 19739126
[TBL] [Abstract][Full Text] [Related]
20. A molecular mimic of phosphorylated prolactin (S179D PRL) secreted by eukaryotic cells has a conformation with an increased positive surface charge compared to that of unmodified prolactin.
Ueda EK; Soares CR; Bartolini P; DeGuzman A; Lorenson MY; Walker AM
Biochemistry; 2009 Jul; 48(29):6887-97. PubMed ID: 19555049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
